XML 19 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Accounting for Stock-Based Compensation
6 Months Ended
Jun. 30, 2019
Accounting for Stock-Based Compensation [Abstract]  
Accounting for Stock-Based Compensation Disclosure



2.  ACCOUNTING FOR STOCK-BASED COMPENSATION 

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. Amended and Restated 2009 Stock Option and Award Plan, which was amended and restated as of March 14, 2018 and approved by the Company’s stockholders at the annual meeting of stockholders held on May 15, 2018 (the “2009 Plan”).

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which did not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock. Persons eligible to receive grants under the 2000 Plan included the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan were “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurred in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 had a 10-year contractual term, options granted in 2005 through 2007 had an eight-year contractual term and options granted since 2008 had a 10-year contractual term. Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan.

The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term. As of June 30, 2019, 4,970,500 shares of unissued common stock were reserved for future grants under the 2009 Plan.

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date. 

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

 



 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



Three Months Ended

 

Six Months Ended



June 30,

 

June 30,



2019

 

2018

 

2019

 

2018

Effect on loss before income taxes

$

(3)

 

$

(3)

 

$

(6)

 

$

(7)

Effect on net loss

$

(2)

 

$

(2)

 

$

(4)

 

$

(4)



 

 

 

 

 

 

 

 

 

 

 

At June 30, 2019, $19 million of unrecognized stock-based compensation expense related to outstanding unvested stock options, restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 26 months. Of that amount, $2 million related to outstanding unvested stock options was expected to be recognized over a weighted-average period of 32 months and $17 million related to outstanding unvested restricted stock and restricted stock units was expected to be recognized over a weighted-average period of 25 months. There were no modifications to awards during the three or six months ended June 30, 2019 and 2018.

The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the three and six months ended June 30, 2019:







 

 

 

 

 



Three Months Ended

 

Six Months Ended



June 30, 2019

 

June 30, 2019

Expected volatility

67.5 

%

 

68.4 

%

Expected dividends

 -

 

 

 -

 

Expected term

6 years

 

 

5.6 years

 

Risk-free interest rate

1.9 

%

 

2.6 

%



In determining the expected term, the Company examined concentrations of option holdings and historical patterns of option exercises and forfeitures, as well as forward-looking factors, in an effort to determine if there were any discernable employee populations. From this analysis, the Company identified two primary employee populations, one consisting of certain senior executives and the other consisting of substantially all other recipients.

The expected volatility rate was estimated based on historical volatility. In determining expected volatility, the Company also reviewed the market-based implied volatility of actively traded options of its common stock and determined that historical volatility utilized to estimate the expected volatility rate did not differ significantly from the implied volatility.

The expected term computation is based on historical exercise and cancellation patterns and forward-looking factors, where present, for each population identified. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company adjusts the estimated forfeiture rate to its actual experience.

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of June 30, 2019, and changes during each of the three-month periods following December 31, 2018, were as follows (in millions, except share and per share data):

 



 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

 

 

 

Weighted-

 

Aggregate



 

 

 

 

Average

 

Intrinsic   



 

 

Weighted-

 

Remaining

 

Value as of



 

 

Average

 

Contractual

 

June 30,



Shares

 

Exercise Price

 

Term

 

2019

Outstanding at December 31, 2018

624,938 

 

$

31.21 

 

 

 

 

 

Granted

646,500 

 

 

4.99 

 

 

 

 

 

Exercised

 -

 

 

 -

 

 

 

 

 

Forfeited and cancelled

(92,301)

 

 

25.57 

 

 

 

 

 

Outstanding at March 31, 2019

1,179,137 

 

 

17.27 

 

 

 

 

 

Granted

12,000 

 

 

2.66 

 

 

 

 

 

Exercised

 -

 

 

 -

 

 

 

 

 

Forfeited and cancelled

(30,834)

 

 

31.94 

 

 

 

 

 

Outstanding at June 30, 2019

1,160,303 

 

$

16.73 

 

6.2 years

 

$

-

Exercisable at June 30, 2019

501,803 

 

$

32.20 

 

1.5 years

 

$

-

The weighted-average grant date fair value of stock options granted during the three and six months ended June 30, 2019 was $1.63 and $2.36, respectively. No stock options were granted during the three and six months ended June 30, 2018. The aggregate intrinsic value (calculated as the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($2.67) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on June 30, 2019. This amount changes based on the market value of the Company’s common stock. There were no options exercised during the three or six months ended June 30, 2019 and 2018. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. 

The Company has also awarded restricted stock under the 2009 Plan to employees of certain subsidiaries. With respect to time-based vesting restricted stock that has been awarded under the 2009 Plan, the restrictions on these shares have generally lapsed in one-third increments on each of the first three anniversaries of the award date. In addition, certain of the restricted stock awards granted to the Company’s senior executives have contained performance objectives required to be met in addition to any time-based vesting requirements. If the applicable performance objectives are not attained, these awards will be forfeited in their entirety. For such performance-based awards granted prior to March 1, 2017, performance objectives were measured over a one-year period, and, provided the target performance objective was attained, restrictions lapsed in one-third increments on each of the first three anniversaries of the award date. For performance-based awards granted on or after March 1, 2017, the performance objectives have been measured cumulatively over a three-year period. With respect to performance-based awards granted on or after March 1, 2017, if the applicable target performance objective is met at the end of the three-year period, then the portion of the restricted stock award subject to such performance objective will vest in full on the third anniversary of the award date. Additionally, for these awards, based on the level of achievement for the applicable performance objective within the parameters specified in the award agreement, the number of shares to be issued in connection with the vesting of the award may be adjusted to decrease or increase the number of shares specified in the original award. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2009 Plan may lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance objectives that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied. 

Restricted stock outstanding under the 2009 Plan as of June 30, 2019, and changes during each of the three-month periods following December 31, 2018, were as follows:

 



 

 

 

 



 

 

 

 



 

 

Weighted-



 

 

Average Grant



Shares

 

Date Fair Value

Unvested at December 31, 2018

3,308,907 

 

$

7.00 

Granted

1,958,000 

 

 

4.97 

Vested

(983,986)

 

 

9.17 

Forfeited

(57,335)

 

 

6.37 

Unvested at March 31, 2019

4,225,586 

 

 

5.56 

Granted

17,000 

 

 

2.66 

Vested

(62,665)

 

 

8.52 

Forfeited

(19,334)

 

 

4.72 

Unvested at June 30, 2019

4,160,587 

 

 

5.51 

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2000 Plan and the 2009 Plan. On March 1, 2018, each of the Company’s outside directors received a grant under the 2009 Plan of 37,118 RSUs. On March 1, 2019, each of the Company’s outside directors received a grant under the 2009 Plan of 34,068 RSUs. Each of the 2018 and 2019 grants had a grant date fair value of approximately $170,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date or upon the director’s earlier cessation of service on the board, other than for cause.  

RSUs outstanding under the 2009 Plan as of June 30, 2019, and changes during each of the three-month periods following December 31, 2018, were as follows:

 



 

 

 

 



 

 

 

 



 

 

Weighted-



 

 

Average Grant



Shares

 

Date Fair Value

Unvested at December 31, 2018

397,906 

 

$

6.17 

Granted

306,612 

 

 

4.99 

Vested

(162,942)

 

 

7.42 

Forfeited

 -

 

 

 -

Unvested at March 31, 2019

541,576 

 

 

5.13 

Granted

 -

 

 

 -

Vested

 -

 

 

 -

Forfeited

 -

 

 

 -

Unvested at June 30, 2019

541,576 

 

 

5.13